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Abstract
Background—Biliary complications after liver transplant are a frequent source of morbidity.
However, little recent mortality data exists related to endoscopic management of these
complications.
Aims—To determine the effect of endoscopic retrograde cholangiopancreatography (ERCP)
utilization and biliary complications on patient and graft survival after liver transplantation.
Methods—This study was a retrospective cohort study at the University of North Carolina
Hospitals from 2004 to 2007. One hundred thirty-two consecutive liver transplant patients were
included. Recipient, donor, and clinical data were extracted from electronic resources. The main
outcome measurements were all-cause mortality and graft failure.
Results—Of 132 transplants, 59 (45%) required ERCP post transplant, and 49 (37%) were found
to have a biliary complication by ERCP. The 1-year patient survival for those treated by ERCP
with a biliary complication was 90% compared with 81% in those without a biliary complication
[P = 0.018; unadjusted hazard ratio (HR) = 0.32; 95% confidence interval (CI) 0.11–0.93]. The 1-
year graft survival in those with and without a biliary complication was 94% and 73%,
respectively (P < 0.001; unadjusted HR 0.19; 95% CI 0.07–0.56). This effect on patient and graft
survival persisted after multivariate analysis. Similar results were seen for ERCP utilization alone,
and when early deaths within the first 30 days were excluded.
Conclusions—Patients who underwent ERCP for a biliary complication post liver
transplantation had better overall and graft survival than patients who did not have an ERCP.
Biliary complications and ERCP utilization are common after liver transplant, but they do not
confer excess mortality.
Keywords
Liver transplantation; Endoscopic retrograde cholangiopancreatography; ERCP; Biliary
complication; Mortality
Introduction
Biliary complications after liver transplant are common, having been reported in 6–51% of
cases [1-3]. These complications, which include anastomotic strictures, ischemic-type
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biliary lesions, choledocholithiasis or bile casts, bile leaks, and cholangitis, are a major
source of morbidity following transplant. The degree of mortality associated with these
problems, however, is less well established. Initial series investigating this included surgical
management strategies used at the beginning of the liver transplant era, and found a
mortality rate of 6.5–44% attributable to biliary complications over 12 months [4-11].
Because these studies predate the era of frequent utilization of endoscopic retrograde
cholangiopancreatography (ERCP) in the management of post-transplant biliary
complications, they may no longer be applicable to current clinical practice.
When biliary complications occur after liver transplantation in the current era, ERCP is now
the first-line therapeutic intervention, and surgical correction of biliary complications is now
typically an option of last resort [12]. ERCP allows effective treatment of anastomotic or
ischemic strictures via stenting programs, clearance of debris from bile ducts, and treatment
of bile leaks and cholangitis [13]. However, there are tangible risks to this procedure,
including cardiopulmonary complications from sedation, bleeding, infection, perforation,
and pancreatitis, which may counteract the presumed benefits [14].
It was our clinical impression that increasing numbers of ERCPs were being performed post
transplant at our center, but that the benefits of this strategy were not well established.
Therefore, the aim of this study is to determine the effect of ERCP utilization and biliary
complications on patient and graft survival post liver transplantation. We hypothesized that
the need for ERCP post transplant and the development of biliary complications would be a
significant source of graft failure as well as increased patient morbidity and mortality.
Methods
Consecutive adult (recipient age ≥18 years) liver transplants performed at the University of
North Carolina (UNC) Hospitals between 27 March 2004 and 4 December 2007 were
identified via UNC’s transplant database, TransChart (TransChart, LLC, Dublin, OH). All
data were analyzed over this same time period plus an additional 5-month follow-up period
through 4 May 2008 to allow for adequate follow-up time to capture ERCP. ERCP
procedure data were obtained through our electronic procedure database, ProvationMD
(Provation Medical, Minneapolis, MN). Further data were obtained via the United Network
of Organ Sharing (UNOS) database and from electronic patient medical records where
appropriate. Data collection was performed after approval from the University of North
Carolina Institutional Review Board.
After determining which patients underwent ERCP and quantifying the number of
procedures they required during the study timeframe, the presence and type of biliary
complications were recorded. These included: bile leak or biloma, intra- or extrahepatic
biliary stricture from any cause, and obstructing stone or bile cast/sludge. Therapeutic
maneuvers during the ERCP were also recorded.
The main outcomes of the study were all-cause mortality and graft failure. Vital status was
determined by review of electronic medical records, and cause of death was determined
through independent chart review by two investigators (A.S.B. and C.B.M.); discrepancies
were adjudicated by all of the investigators. Graft failure was defined as progressive hepatic
dysfunction requiring retransplant or leading to patient death.
Other factors of interest, as well as potential confounders, included recipient demographics
and clinical information [cause of liver failure and model for end-stage liver disease
(MELD) score at transplant], donor characteristics (age, donor type, and donor cause of
death), and operative parameters (warm and cold ischemia time).
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Statistical analyses were performed using Stata (version 9.2; Statacorp, College Station,
TX). Descriptive statistics were used to characterize the study subjects. For bivariate
analysis, chi-square was used for categorical variables and Student’s t-test was used for
continuous variables. Kaplan–Meier survival analysis was performed, censoring patients at
time of death, time of graft failure, or end of study period, to determine 1- and 3-year patient
and graft survival. Multivariate analysis with Cox proportional-hazards modeling was used
to calculate hazard ratios (HR) adjusted for potential confounding factors. These included
recipient race, sex, age, MELD score, indication for transplant, warm and cold ischemia
time, donor age, donor sex, and type of donor (cadaveric or donation after cardiac death). In
order to fully characterize the findings, all analyses were performed for both outcomes, as
well as for ERCP status, presence of a biliary complication, and vital status. Missing data
were minimal in our data set, but subjects with missing data points were excluded from
bivariate and multivariate analysis.
Results
Patient, Donor, and Transplant Characteristics
A total of 132 transplants were performed during the study period, 12 (9%) of which were
retransplants (Table 1). Mean age at transplant was 53 years, 69% of recipients were male,
and 73% were Caucasian. Mean MELD score at transplant was 25. The leading indication
for transplant was chronic hepatitis C infection (20%), followed by cryptogenic cirrhosis
(17%), comorbid hepatitis C and alcohol (12%), and alcohol alone (11%). For analysis, the
etiologies of liver disease were put into four major groups: acute hepatic failure (AHF, 2%),
chronic viral hepatitis (hepatitis B, C, and alcohol plus hepatitis C, 39%), alcohol-induced
liver disease (ETOH, 11%), and others including cryptogenic cirrhosis and nonalcoholic
fatty liver disease (48%).
Mean donor age was 36 years, and 60% were male. Of donors, 82% were traditional
cadaveric donors and 17% were donations after cardiac death (DCD). No living-donor liver
transplants were performed during the study period. Mean cold ischemic time was 419 min
(7 h), and mean warm ischemia time was 41 min. Overall 1- and 3-year graft survival was
81% and 74%, respectively. Overall 1- and 3-year patient survival was 85% and 81%,
respectively.
ERCP Utilization and Effect on Survival
A total of 59 (45%) of the transplant recipients underwent ERCP post transplant, and 44
(33%) had more than one ERCP. The maximum number of ERCPs performed on a single
patient during the study timeframe was ten. Overall, 5 ERCPs (8%) occurred within 1 week
of transplant, 12 (20%) within 2 weeks, and 23 (39%) within 1 month after transplant. There
was no difference in the number of ERCPs performed per year, and all procedures were
performed by the same cohort of four highly experienced biliary endoscopists during the
study period.
Patients who required an ERCP had comparable demographic, clinical, donor, and operative
characteristics to those who did not (Table 1). While there were no differences in cause of
death between the two groups, all of the patients who required retransplant came from the
group of patients who did not receive an ERCP (12 versus 0, P = 0.001).
Survival times also differed between groups. For those who underwent any ERCP, the 1-
and 3-year patient survival was 93% and 90%, respectively, compared with 78 and 75% (P <
0.001) in the no-ERCP group (unadjusted HR = 0.31, 95% CI 0.11–0.82). The Kaplan–
Meier survival curve is shown in Fig. 1. This effect on patient survival persisted after
adjusting for potential recipient, operative, and donor confounders (HR = 0.21, 95% CI
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0.06–0.72, P = 0.013). Similarly, the 1- and 3-year graft survival in the any-ERCP group
was 93% and 90%, respectively, compared with 69% and 61% (P < 0.001) in the no-ERCP
group (unadjusted HR = 0.19; 95% CI 0.07–0.49, P = 0.001). This effect also persisted after
multivariate analysis (HR = 0.20, 95% CI 0.06–0.68, P = 0.010). The hazard ratio was
similar for patients who underwent multiple ERCPs, but did not reach statistical significance
due to a smaller sample size (Table 2).
Biliary Complications and Effect on Survival
A total of 49 (37%) of patients had a biliary complication identified by ERCP at some point
after transplant. Extrahepatic strictures were the most common finding on first ERCP,
detected in 25 (42%) of cases, followed by bile leaks in 13 (22%) and stones/debris in 5
(8%). Ten (17%) of the initial ERCPs were interpreted as normal post-transplant anatomy
and did not require specific action. The most common intervention was stent placement,
occurring in 39 (66%) of cases, followed by sphincterotomy in 7 (12%) cases and balloon
sweep in 3 (5%) cases. There were no differences in patient or graft survival based on either
ERCP finding or maneuver.
Patients who had a biliary complication treated by ERCP had generally comparable
demographic, clinical, donor, and operative characteristics to those who did not (Table 3).
There were no differences in cause of death between the two groups. Notable differences,
however, were that more patients who received organs from male donors (72% versus 53%,
P = 0.04) had biliary complications, and none of the patients who required retransplant had
biliary complications (0 versus 12, P = 0.005).
There were also survival differences based on the presence of biliary complications treated
by ERCP. For those who had any biliary complication, the 1- and 3-year patient survival
was 94% and 91%, respectively, compared with 81% and 76% (P = 0.03) in the no-biliary-
complication group (unadjusted HR = 0.32; 95% CI 0.11–0.93, P = 0.037). This effect on
patient survival persisted after adjusting for potential recipient, operative, and donor
confounders (HR = 0.18; 95% CI 0.04–0.72, P = 0.018). The Kaplan–Meier survival curve
is shown in Fig. 2. Similarly, the 1- and 3-year graft survival in the biliary complication
group was 94% and 91%, respectively, compared with 73% and 64% (P = 0.007) in the no-
biliary-complication group (unadjusted HR = 0.19; 95% CI 0.07–0.56, P = 0.002). This
effect also persisted after multivariate analysis (HR = 0.19, 95% CI 0.05–0.74, P = 0.017).
Excluding death and graft loss in the first 30 days after transplant did not change the trend
demonstrated in the primary analysis (data not shown).
A total of 30 patients had a percutaneous transhepatic cholangiogram (PTC) during the study
period. There were no significant differences in demographic, clinical, donor, and operative
characteristics between those who did and did not receive a PTC. Sixteen of these 30 (53%)
patients also had an ERCP. The majority (60%) of the PTCs were performed on patients
transplanted during the first half of the study period, and only one was performed on a
patient transplanted in the final 6 months of the study period. There was no difference in
survival between the group of patients who received PTC (HR = 1.15; CI 0.45–2.9, P =
0.77) and those who did not.
Vital Status Analysis
Bivariate analysis was performed to further investigate differences between the study
patients who lived and those who died (Table 4). Overall, there were 23 (17%) deaths during
the study period. Patients transplanted at older age (56 years versus 52 years, P = 0.04) were
more likely to die. Patients who died tended to have longer cold ischemia times (465 versus
410 min, P = 0.052). The main cause of death was the “other” category, which included 11
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(48%) deaths attributed to graft versus host disease, trauma, stroke, pulmonary
complications, and unknown causes of death. Four (17%) of those who died succumbed to
cardiac complications, and an equal number died of biliary complications, primarily
progressive intrahepatic vanishing ducts and cholangitis. On multivariate modeling, the only
independent predictors of remaining alive during the study period were having an ERCP,
experiencing a biliary complication, younger age at transplant, and lower MELD score.
Discussion
Because biliary complications are common after liver transplantation and often require
treatment with repeated invasive endoscopic procedures, this study aimed to determine the
effect of ERCP utilization and the presence of biliary complications on patient and graft
survival post liver transplantation. To our surprise, and in contrast to the original hypothesis,
we found that patients who required ERCP after transplantation had better survival than
those who did not, and that this also held for patients found to have biliary complications
after transplant.
What might explain this somewhat counterintuitive result? In the literature, multiple
publications and abstracts allude to the significant morbidity and mortality attributable to
biliary complications after liver transplant. Biliary complications are reported to occur in 6–
51% of liver transplants [1-3], and we found that at our center, 45% of patients underwent at
least one ERCP, and 36% had a biliary complication defined as a bile leak, stricture, stone,
or “other” finding. Thus, biliary morbidity was as common in our center as cited in the
literature.
While the morbidity is well established, it appears that most data attributing mortality to
biliary complications predate the era of routine endoscopic management. Specifically, Kuo
et al. cite a biliary complication rate of 25% with an associated 1-year mortality of 43.5%
[11], and Stratta et al. report 76% actuarial 1-year survival among patients with biliary
complications [5]. Because of these data, Ororio, et al. were among the first to advocate
nonoperative management of biliary complications through endoscopic and interventional
radiographic approaches [12]. Since then, other authors have advocated frequent and
aggressive use of endoscopic management of biliary complication [15-17], yet there have
been few reports delineating the mortality related to biliary complications. Those reports that
do include mortality data, such as those of Rizk et al. and Pfau et al., cite no difference
between biliary sources of mortality and other causes [18, 19].
Could our finding that post-transplant ERCP was independently associated with better
patient and graft survival represent an epiphenomenon? This is unlikely with such strongly
protective hazard ratios in the 0.2–0.3 range. We believe that selection bias is similarly
unlikely. While it is theoretically possible that those who received ERCP may not have been
as sick as those who did not, this is not borne out in practice. At our center, ERCP are
performed in the operating room under general anesthesia, or at the bedside in the Surgical
Intensive Care Unit when indicated. Indeed, the first ERCP in this series was performed just
5 days post transplant, and no patients were denied a diagnostic or therapeutic procedure due
to comorbidities.
Even when excluding death and graft loss in the first 30 days after transplant, the point
estimate for the hazard ratio associated with biliary complications remains similar. This
adjustment is overcompensation for selection bias, however. While it excludes early deaths
and patients who theoretically may have been too sick to undergo a procedure, it also
excludes 39% of our population who did undergo a procedure and ignores those who
received benefit from aggressive early endoscopic management of operative complications.
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We also perform ERCP on patients with prior hepaticojejunostomy or Roux en-Y
anastomoses via traditional or single-balloon methods [20]. Given the richness of our data
sources, misclassification bias is also unlikely. Furthermore, that the observed relationships
hold after adjusting for multiple confounding factors lends strength to the finding.
The interpretation of these results may in fact be relatively simple. In the current era of
aggressive management of biliary complications via ERCP, biliary complications are
common, but not life-threatening. Moreover, undergoing therapeutic ERCP to treat biliary
complications, even if this is required on multiple occasions, may attenuate the adverse
effects that such complications have on patient and graft survival. Conversely, complications
that are not amenable to ERCP, such as hepatic artery thrombosis, chronic rejection, or
infections in the setting of profound immunosuppression, confer a risk that is not easily
mitigated by an endoscopic intervention.
In conclusion, this retrospective cohort study of post-liver-transplant patients shows that
patients who received an ERCP for endoscopic management of a biliary complication had
lower rates of graft failure and death than those who did not have an ERCP. The
implications of these results are that, in the era of endoscopic management, biliary
complications are a substantial source of morbidity post transplant, but they do not confer
excess mortality, likely because these complications can be effectively treated by ERCP and
do not portend the same mortality as other complications associated with liver transplant.
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Kaplan–Meier survival estimates by ERCP
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Kaplan–Meier survival estimates by biliary complication
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Table 1
Characteristics of the study population and bivariate analysis of patients who received ERCP versus those who
did not
Total population (n = 132) Any ERCP (n = 59) No ERCP (n = 73) P for any ERCP versus
no ERCP
Recipient characteristics
Mean age at transplant (years) 52.8 ± 8.9 53.3 ± 8.6 52.4 ± 9.2 0.54
Male, n (%) 91 (69) 42 (71) 49 (67) 0.62
Caucasian, n (%) 96 (73) 40 (78) 56 (76) 0.25
Indication for transplant, n (%)
 AHF 3 (2) 2 (3) 1 (1)
 Viral 51 (39) 22 (37) 29 (40) 0.50
 ETOH 15 (11) 9 (15) 6 (8)
 Other 63 (48) 26 (44) 37 (51)
MELD score 24.8 ± 7.1 25.7 ± 7.3 24.0 ± 7.0 0.16
Donor characteristics
Male donor, n (%) 74 (60) 36 (64) 38 (57) 0.39
Donor age (years) 35.7 ± 15.0 35.1 ± 14.8 36.1 ± 15.3 0.72
Donor type
 Cadaveric 108 (82) 61 (83) 47 (80) 0.50
 DCD 23 (17) 11 (15) 12 (20)
 Unknown 1 (1) 1 (1) 0 (0)
Donor cause of death, n (%)
 Anoxia 9 (7) 5 (9) 4 (6)
 Cerebral vascular accident (CVA) 48 (39) 22 (39) 26 (38) 0.91
 Trauma 62 (50) 27 (48) 35 (51)
 Unknown 5 (4) 2 (4) 3 (4)
Operative characteristics
Warm ischemia time, min 40.5 ± 10.8 40.5 ± 12.9 40.5 ± 8.8 0.99
Cold ischemia time, min 419.3 ± 121.3 430 ± 122 411 ± 121 0.38
Required retransplant, n (%) 12 (9) 0 (0) 12 (16) 0.001
Survival
Graft survival, %
 1 year 81 92.8 69.3 <0.0001
 3 years 74 90.4 60.8
Patient survival, %
 1 year 85 92.8 77.5 0.01
 3 years 81 90.4 74.7
Patient cause of death, n (%)
 Graft failure/1* liver disease 2 1 (20) 1 (6)
 Infection/sepsis 2 0 (0) 2 (11)
 Cardiac 4 0 (0) 4 (22) 0.34
 Biliary complication 4 2 (40) 2 (11)
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Total population (n = 132) Any ERCP (n = 59) No ERCP (n = 73) P for any ERCP versus
no ERCP
 Other 11 2 (40) 9 (50)
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Table 2
Crude and adjusted hazard ratios for graft failure and death
Hazard ratio (95% CI)
Graft failure P Death P
Risk of graft failure and death, unadjusted (crude) model (n = 132)
Any ERCP 0.19 (0.07–0.49) 0.001 0.31 (0.11–0.82) 0.019
>1 ERCP 0.24 (0.08–0.69) 0.008 0.39 (0.13–1.14) 0.086
Biliary complication 0.19 (0.07–0.56) 0.002 0.32 (0.11–0.93) 0.037
Risk of graft failure and death, full model* (n = 122)
Any ERCP 0.20 (0.06–0.68) 0.010 0.21 (0.06–0.72) 0.013
>1 ERCP 0.33 (0.9–1.20) 0.092 0.34 (0.9– 1.26) 0.11
Biliary complication 0.19 (0.05–0.74) 0.017 0.18 (0.04–0.72) 0.018
*
Adjusted for age at transplant, sex, race, MELD score, liver–kidney transplant, need for retransplant, indication for transplant, warm ischemia
time, cold ischemia time, type of donor, donor age, and donor cause of death
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Table 3
Bivariate analysis of patients who had a biliary complication versus those who did not
Biliary complication (n = 49) No biliary complication (n = 83) P
Recipient characteristics
Mean age at transplant (years) 53.3 ± 8.5 52.5 ± 9.2 0.63
Male, n (%) 35 (71) 56 (67) 0.64
Caucasian, n (%) 17 (35) 19 (23) 0.14
Indication for transplant, n (%)
 AHF 2 (4) 1 (1)
 Viral 19 (39) 32 (39) 0.31
 ETOH 8 (16) 7 (8)
 Other 20 (41) 43 (52)
MELD score 26.0 ± 7.1 24.0 ± 7.1 0.12
Donor characteristics
Male donor, n (%) 33 (72) 41 (53) 0.04
Donor age (years) 34.8 ± 14.7 36.2 ± 15.3 0.61
Donor type
 Cadaveric 39 (80) 69 (83)
 DCD 10 (20) 13 (16) 0.60
 Unknown 0 (0) 1 (1)
Donor cause of death, n (%)
 Anoxia 4 (9) 5 (6)
 CVA 14 (30) 34 (44) 0.54
 Trauma 26 (57) 36 (46)
 Unknown 2 (4) 3 (4)
Operative characteristics
Warm ischemia time, min 41 ± 14 40 ± 9 0.66
Cold ischemia time, min 421 ± 122 418 ± 122 0.89
Required retransplant, n (%) 0 12 (14) 0.005
Survival
Graft survival, %
 1 year 93.5 73.4 0.0007
 3 years 90.6 63.9
Patient survival, %
 1 year 93.5 80.5 0.03
 3 years 90.6 75.5
Patient cause of death, n (%)
 Graft failure/1* liver disease 1 (25) 1 (5)
 Infection/sepsis 0 (0) 2 (11)
 Cardiac 0 (0) 4 (21) 0.18
 Biliary complication 2 (50) 2 (11)
 Other 1 (25) 10 (53)
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Table 4
Bivariate analysis of those patients who lived versus those who died
Alive (n = 109) Deceased (n = 23) P
Recipient characteristics
Age at transplant, mean ± SD (years) 52.1 ± 9.4 56.3 ± 5.6 0.04
Male, n (%) 77 (71) 14 (61) 0.36
Caucasian, n (%) 78 (72) 18 (78) 0.51
Indication for transplant, n (%)
 AHF 2 (2) 1 (4) 0.82
 Viral 43 (39) 8 (35)
 ETOH 13 (12) 2 (9)
 Other 51 (47) 12 (52)
MELD score 24.3 ± 6.8 26.9 ± 8.3 0.11
Donor characteristics
Male donor, n (%) 62 (61) 12 (57) 0.76
Donor age (years) 35.7 ± 15.0 35.6 ± 15.7 0.98
Donor type
 Cadaveric 86 (79) 22 (96)
 DCD 22 (20) 1 (4) 0.17
 Unknown 1 (1) 0 (0)
Donor cause of death, n (%)
 Anoxia 6 (6) 3 (14)
 CVA 44 (43) 4 (19) 0.17
 Trauma 49 (48) 13 (62)
 Unknown 4 (4) 1 (5)
Operative characteristics
Warm ischemia time, min 41 ± 11 40 ± 7 0.70
Cold ischemia time, min 410 ± 120 465 ± 120 0.052
Any ERCP, n (%) 54 (50) 5 (22) 0.015
Finding at first ERCP
 Nothing/normal 9 (17) 1 (20)
 Intrahepatic stricture(s) 1 (2) 0 (0)
 Stone 5 (9) 0 (0) 0.92
 Bile leak 12 (22) 1 (20)
 Extrahepatic stricture(s) 23 (43) 2 (40)
 Other 4 (7) 1 (20)
Maneuver at first ERCP
 None 8 (14) 2 (40)
 Sphincterotomy 7 (13) 0 (0)
 Balloon sweep 3 (6) 0 (0) 0.45
 Stent placement 36 (67) 3 (60)
 Other 0 (0) 1 (20)
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Alive (n = 109) Deceased (n = 23) P
Multiple ERCP, n (%) 40 (37) 4 (17) 0.07
Biliary complication, n (%) 45 (41) 4 (17) 0.03
Required retransplant, n (%) 8 (7) 4 (17) 0.13
Patient cause of death
 Graft Failure/1* liver disease 2 (9)
 Infection/sepsis 2 (9)
 Cardiac N/A 4 (17) N/A
Biliary complication 4 (17)
Other 11 (48)
Dig Dis Sci. Author manuscript; available in PMC 2013 September 19.
